Targeted Alpha Therapy Symposium

Name: Targeted Alpha Therapy Symposium
Start: 2019-04-01T08:00:00+00:00
End: 2019-04-05T18:00:00+00:00
Location: Fairmont Château Laurier Hotel

Apr 1–5, 2019

Fairmont Château Laurier Hotel

UTC timezone

Author List

Rebecca Abergel
- Author in Actinium Biokinetics and Dosimetry: What is the Impact of Ac-227 in Accelerator-Produced Ac-225?
- Author in Challenges of actinium coordination chemistry for nuclear medicine
- Co-author in Bioconjugation of actinides using a peptoid scaffold
Diane Abou
- Author in Automated Production of Alpha-Emitting Therapeutic Radionuclides
- Co-author in Application of a trabecular and cellular model of bone marrow dosimetry for targeted 223Ra therapy
Alyson Abraham
- Author in Evaluation of inorganic ion exchange materials for purification of 225Ac from thorium and radium radioisotopes
abdelmjid Aiboud
- Author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Cole Aidan
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
mouhsine Ait said
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Per Albertsson
- Author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
- Co-author in Astatine-211: The Chemistry Infrastructure
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
Barry Allen
- Author in Generic MUC1 Epitope for Targeted Alpha Therapy of Metastatic Cancer
Kevin Allen
- Author in The Use of Radioimmunotherapy for the Treatment of Metastatic Melanoma
- Co-author in Development of novel radiopharmaceuticals to combat invasive fungal infections
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
- Co-author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
Kevin Allen
- Co-author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
Amer A. Al Qaaod
- Author in Numerical Investigation of Th-229 Production in an Accelerator Driven System Reactor
Ali Alshehri
- Author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
Eduardo Aluicio-Sarduy
- Co-author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
Dahlia An
- Co-author in Actinium Biokinetics and Dosimetry: What is the Impact of Ac-227 in Accelerator-Produced Ac-225?
Oleg Andreev
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
- Co-author in Production and Quality Control of 223RaCl2 and 224RaCl2
Emma Aneheim
- Author in Poly-L Lysine based Approaches for Pretargeted Radioimmunotherapy with Astatine-211
- Co-author in A Novel Reaction for “Click”-based 211At-Astatination
- Co-author in Astatine-211: The Chemistry Infrastructure
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
Miho Aoki
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Christos Apostolidis
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
EMMANUEL NYARKO APPIAH
- Author in HOPE FOR PATIENTS WITH PROSTATE CANCER WITH BONE METASTASES
Kazuharu ARAKAWA
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
Yasushi ARANO
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Lior Arazi
- Author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Leticia Arnedo-Sanchez
- Author in Challenges of actinium coordination chemistry for nuclear medicine
Jon Aro
- Author in Safe use of Ra-223 radium dichloride (223Ra) across a wide-range of clinical scenarios: A 10-year single-institution radiation safety experience.
Ehab Atallah
- Author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Zachery Austin
- Co-author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
zine el abidine Ayaz
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Tom Back
- Author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
- Co-author in Astatine-211: The Chemistry Infrastructure
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Sergio Baldari
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Kris Barreto
- Author in Depleting the latent HIV-1 cell population using 225Ac-labeled anti-CD4+ targeted radioimmunoconjugates
Enrique Batista
- Co-author in Coordination Chemistry of +3 Actinium
David Bauer
- Author in Calixarene based ligands for Radium and Barium
- Co-author in Synthesis and Functionalization of Radium-doped Barium Sulfate Nanoparticles
Victor Bautista
- Author in Production and Chemical Separation of No Carrier Added (nca) Lutetium-177.
Inga Bayh
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Kebede Begna
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Ali Beheshti
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Joaquim Bellmunt
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Nadia Benabdallah
- Author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
François Bénard
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
kaddour Benhamou
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Ran Ben-Hur
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Mohamed Benmerrouche
- Co-author in FLUKA simulation of Ac-225 production with a medical cyclotron
Paul Benny
- Co-author in Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory
naoual Bentaleb
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Marion BERDAL
- Co-author in Advances in the radiolabeling of antibodies with astatine-211: toward simplified procedures and improved radiochemical yields
Mark Berger
- Author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
- Co-author in Impact of Target Cell Number on Target cell and Tissue Dose for Antibody-Mediated delivery of Alpha-Emitters
Michela Bernardini
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Jean-Marc Bertho
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Nikolay Betenekov
- Co-author in Various chromatographic schemes for separation of 213Bi from 225Ac
Rishi Bhandia
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Eva Birnbaum
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Coordination Chemistry of +3 Actinium
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Ariana Bitton
- Co-author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
Roger M Bjerke
- Co-author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Wesley Bolch
- Co-author in Application of a trabecular and cellular model of bone marrow dosimetry for targeted 223Ra therapy
Luke Bolek
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
rose boll
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Comparison of Reactor Production of 229Th vs. Accelerator Production of 229Th at Oak Ridge National Laboratory
- Co-author in Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory
Tebatso Boshomane
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
David Bottomley
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Michael Brands
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
Victoria Brown
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
M. Alex Brown
- Co-author in Development of 211At production via continuous extraction of 211Rn
Frank Bruchertseifer
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
- Co-author in Alpha-particle nanotherapeutics against recurrent, chemoresistant Triple Negative Breast Cancer
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
- Co-author in Improved tumor control and absence of late neurotoxicity using alpha (213Bi) as compared to beta (90Y) labelled-DOTA-Substance P for the treatment of low grade gliomas
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
Ruth Bryan
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
S Buhl
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
Eric Burak
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Mark Burger
- Co-author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
Paige E. Burrell
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Irina Butkaliuk
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
- Co-author in Capabilities of JSC “SSC RIAR” in Producing 227ThCl4
Pavel Butkaliuk
- Author in Alternative Options to Produce 225Ac for Nuclear Medicine
- Author in Capabilities of JSC “SSC RIAR” in Producing 227ThCl4
- Author in Production and Quality Control of 223RaCl2 and 224RaCl2
Byung Hyun Byun
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Campfield Caoimhghin
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
Joe Capri
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Thomas Cardinaels
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
- Co-author in Ra-226/Ac-225 chemical separation R&D at SCK•CEN
- Co-author in The strategic plans of SCK•CEN towards a routine production of 225Ac from 226Ra
Joan Carles
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sean D. Carlin
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Dametra Catalano
- Author in Evaluation of inorganic ion exchange materials for purification of 225Ac from thorium and radium radioisotopes
Patrick Causey
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
- Co-author in Selective Separation of Radium and Actinium from Bulk Thorium Target Material
Vicky Caveliers
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Edyta Cedrowska
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
Anne Chauchereau
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Chin-Tu Chen
- Co-author in Development of 211At production via continuous extraction of 211Rn
Michel Cherel
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Michel CHÉREL
- Co-author in Advances in the radiolabeling of antibodies with astatine-211: toward simplified procedures and improved radiochemical yields
Joon Ho Choi
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Chang Woon Choi
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Partha Choudhury
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Nicolas Chouin
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Chatzigiannis Christos
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
Dmitry Chuvilin
- Author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Ming-Kuan Chyan
- Co-author in Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
Thomas Elias Cocolios
- Co-author in ISOL technique for the production of 225Ac at CERN-MEDICIS
Rick Coelho
- Co-author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Michel Cogne
- Co-author in Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma
Tomer Cooks
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Jason Cooley
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Roy Copping
- Author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Comparison of Reactor Production of 229Th vs. Accelerator Production of 229Th at Oak Ridge National Laboratory
- Co-author in Production and Chemical Separation of No Carrier Added (nca) Lutetium-177.
- Co-author in Separation of Actinium-225 from Lanthanides Using High Pressure Ion Chromatography
Dominik Cordier
- Co-author in Improved tumor control and absence of late neurotoxicity using alpha (213Bi) as compared to beta (90Y) labelled-DOTA-Substance P for the treatment of low grade gliomas
Bart Cornelissen
- Co-author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Angel Cortez
- Author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
Michael Craig
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Veronique Cruciani
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
Alan Cuthbertson
- Co-author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Cathy S. Cutler
- Author in Evaluation of inorganic ion exchange materials for purification of 225Ac from thorium and radium radioisotopes
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in FLUKA simulation of Ac-225 production with a medical cyclotron
Johannes Czernin
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Ekaterina Dadachova
- Co-author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
Ekaterina Dadachova
- Author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
- Co-author in Assessing Melanin Capabilities in Radiation Shielding and Radioadaptation
- Co-author in Development of novel radiopharmaceuticals to combat invasive fungal infections
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
- Co-author in Glycoprotein 41 targeted radioimmunotherapy as a novel treatment for neuroHIV/AIDS
- Co-author in The Use of Radioimmunotherapy for the Treatment of Metastatic Melanoma
Magnus Dahlbom
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Jostein DAHLE
- Co-author in 212Pb-NNV003 as a novel targeted alpha therapy for CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
Calogero D'Alessandria
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Ashley Dame
- Author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Production and Chemical Separation of No Carrier Added (nca) Lutetium-177.
Tamara Daniels
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Sandra Davern
- Author in Separation of Actinium-225 from Lanthanides Using High Pressure Ion Chromatography
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Marie Davidkova
- Co-author in PRELIMINARY IN-VITRO STUDY OF 223Ra IMPACT ON SELECTED TISSUE AND TUMOR CELL LINES
Wojciech Dawicki
- Co-author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
Wojciech Dawicki
- Author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
Yana Dekempeneer
- Author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
Robin de Kruijff
- Author in Therapeutic efficacy of 225Ac-containing polymersomes
- Co-author in Development of 211At production via continuous extraction of 211Rn
Claire De Labriolle-Vaylet
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Ebrahim Delpassand
- Author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
- Co-author in Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212
Anna Demchenko
- Author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Evgeniy Denisov
- Co-author in Various chromatographic schemes for separation of 213Bi from 225Ac
Christoph Denk
- Author in A Novel Reaction for “Click”-based 211At-Astatination
Antonia Denkova
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
David Denton
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
Aurélie Desbrée
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Matthias D'Huyvetter
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
Matthias D'Huyvetter
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Stephen Dinning
- Co-author in Safe use of Ra-223 radium dichloride (223Ra) across a wide-range of clinical scenarios: A 10-year single-institution radiation safety experience.
Sabina Dizdarevic
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Kristof Dockx
- Author in ISOL technique for the production of 225Ac at CERN-MEDICIS
Patrick Donabedian
- Co-author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Jérôme Donnard
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Clifford Dugal
- Co-author in Implementation of Single Alpha-Particle Traversal Microdosimetric Model
- Co-author in Microdosimetric and Biokinetic Modelling of Alpha-Immuno-Conjugate Transport in Endothelial Cells
Stephanie Durand-Panteix
- Author in Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma
Kumar Deep Dutta
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Thomas Dyke
- Co-author in Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory
Bayirta Egorova
- Co-author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Matthias Eiber
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Dennis Elema
- Co-author in The strategic plans of SCK•CEN towards a routine production of 225Ac from 226Ra
Christine Ellingsen
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Christine Ellingsen
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
Mary Embree
- Co-author in Nanoparticles for the treatment of metastatic non small cell lung cancer with 225Ac
Jonathan Engle
- Co-author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
Stanislav Ermolaev
- Co-author in Production of 230Pa from proton-irradiated thorium and developing 230Pa/230U/226Th tandem generator
- Co-author in Various chromatographic schemes for separation of 213Bi from 225Ac
abdellah Ettabia
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Joanna Fair
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
MICHAEL FASSBENDER
- Author in A dual generator concept to yield 226Th: an isotope of interest for targeted alpha therapy
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Separation of Ac-225 from lanthanide fission products using a reverse phase chromatographic process incorporating a solvent impregnated resin
Benedikt Feuerecker
- Author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Karolína Ficenzová
- Co-author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
Laura Finn
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Jonathan Fitzsimmons
- Author in Evaluation of inorganic ion exchange materials for purification of 225Ac from thorium and radium radioisotopes
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
aziz Flloaui
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
humphrey Fonge
- Co-author in Targeted alpha particle therapy of EGFR-positive breast cancer using site-specifically labeled 225Ac–dN-SpyCatcher-SpyTag-nimotuzumab
John Forbes
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Didier Franck
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Connor Frank
- Author in Assessing Melanin Capabilities in Radiation Shielding and Radioadaptation
Eric Frey
- Co-author in Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225
- Co-author in Impact of Target Cell Number on Target cell and Tissue Dose for Antibody-Mediated delivery of Alpha-Emitters
Eric Frey
- Co-author in Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Masami Fukada
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Koichi Fukase
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
Mitsuhiro Fukuda
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
Kevin Gaddis
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Separation of Actinium-225 from Lanthanides Using High Pressure Ion Chromatography
Gregory Gaehle
- Co-author in Automated Production of Alpha-Emitting Therapeutic Radionuclides
Ravi Gampa
- Co-author in Development of 211At production via continuous extraction of 211Rn
Ravendra Garg
- Author in Glycoprotein 41 targeted radioimmunotherapy as a novel treatment for neuroHIV/AIDS
Stacey Gauny
- Co-author in Actinium Biokinetics and Dosimetry: What is the Impact of Ac-227 in Accelerator-Produced Ac-225?
Weronika Gawęda
- Author in Barium ferrite magnetic nanoparticles labeled with 223Ra: a new potential radiobioconjugate for targeted alpha therapy and magnetic hyperthermia
Denise Gendron
- Co-author in Selective Separation of Radium and Actinium from Bulk Thorium Target Material
Jean-François GESTIN
- Co-author in Advances in the radiolabeling of antibodies with astatine-211: toward simplified procedures and improved radiochemical yields
Michael Ghaly
- Co-author in Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
younes Ghamad
- Co-author in Development of a new method for the microbiological analysis of radiopharmaceuticals case of Iodine 131
Harish Chandra Goel
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Chelsea Goff
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Matthew Gott
- Co-author in Development of 211At production via continuous extraction of 211Rn
Sébastien Gouard
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Derek Grant
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Damian J. Green
- Co-author in Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
John Greene
- Co-author in Development of 211At production via continuous extraction of 211Rn
Amanda Grimm
- Co-author in High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac
Terry Grimm
- Author in High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac
Natalie Grinshtein
- Author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Justin Griswold
- Author in Comparison of Reactor Production of 229Th vs. Accelerator Production of 229Th at Oak Ridge National Laboratory
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Separation of Actinium-225 from Lanthanides Using High Pressure Ion Chromatography
Joseph Grudzinski
- Co-author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
François GUÉRARD
- Author in Advances in the radiolabeling of antibodies with astatine-211: toward simplified procedures and improved radiochemical yields
Amita Gupta
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Manoj Gupta
- Author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Mireille Gysemans
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Ferid HADDAD
- Co-author in Advances in the radiolabeling of antibodies with astatine-211: toward simplified procedures and improved radiochemical yields
Urs B Hagemann
- Co-author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Andersson Håkan
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Andreas Hallqvist
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
Andreas Hallqvist
- Author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Donald K. Hamlin
- Co-author in Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Stefanie Hammer
- Author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Sang Jin Han
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
Lauren Harshman
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
James Harvey
- Author in NorthStar Program for Production of Ac225
- Co-author in Selective Separation of Radium and Actinium from Bulk Thorium Target Material
SUMITAKA HASEGAWA
- Author in Alpha-radioimmunotherapy against liver metastasis of HER2-positive gastric cancer in a mouse model
Kazuyuki Hashimoto
- Co-author in Astatine and iodine chemical species in solutions prepared by dry distillation
Jun Hatazawa
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Bin He
- Author in Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212
Bin He
- Co-author in Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225
- Co-author in Impact of Target Cell Number on Target cell and Tissue Dose for Antibody-Mediated delivery of Alpha-Emitters
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Ahn Heesu
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
Axel Heidenreich
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Stephan Heinitz
- Author in The strategic plans of SCK•CEN towards a routine production of 225Ac from 226Ra
- Co-author in Ra-226/Ac-225 chemical separation R&D at SCK•CEN
Daniel Heinrich
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Muath Helal
- Author in Development of novel radiopharmaceuticals to combat invasive fungal infections
Muath Helal
- Co-author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
Soares Heloisa
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Hartwig Hennekes
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Reinier Hernandez
- Author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
Matthias Herth
- Co-author in A Novel Reaction for “Click”-based 211At-Astatination
Sandra Heskamp
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
Jacob Hesterman
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Helen HEYERDAHL
- Co-author in 212Pb-NNV003 as a novel targeted alpha therapy for CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
Eva Hickman
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
Celestia Higano
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Tatsuya Higashi
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Robert Hobbs
- Author in Application of a trabecular and cellular model of bone marrow dosimetry for targeted 223Ra therapy
- Author in Small Scale Modeling and Dosimetry for the Salivary Gland: Application to 177Lu- and 225Ac-PSMA Therapy
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
Robert Hobbs
- Co-author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
Cornelia Hoehr
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
Jensen Holger
- Co-author in Astatine-211: The Chemistry Infrastructure
E. Philip Horwitz
- Co-author in Selective Separation of Radium and Actinium from Bulk Thorium Target Material
Catherine Hou
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Meiduo Hu
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Soichiro Ichimura
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Takumi Ikeda
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Ohad Ilovich
- Author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Baard Indrevoll
- Co-author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
Noriko, S. ISHIOKA
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
- Co-author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
Hiroshi Ito
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
IGOR I.Y.Galaychuk
- Co-author in HOPE FOR PATIENTS WITH PROSTATE CANCER WITH BONE METASTASES
Lars Jacobsson
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Quiteria Jacquez
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Maciej Jakuciński
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Amirreza Jalilian
- Author in The role of IAEA in the development of radiopharmaceutical sciences with focus on alpha emitters
Ludmila Jandová
- Co-author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
Su Jin Jang
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Nancy Janzen
- Co-author in A Versatile Immune-Stimulatory Actinium-225 Complex for Combination Radiotherapy and Antibody Recruiting Therapy
Holger Jensen
- Author in Production of 211At at the Copenhagen University Hospital, Denmark.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
- Co-author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
Zewei Jiang
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
Rubin Jiao
- Author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
- Co-author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
- Co-author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
- Co-author in The Use of Radioimmunotherapy for the Treatment of Metastatic Melanoma
Kevin John
- Author in US DOE Tri-Lab Research and Production Effort to Provide Accelerator-Produced 225Ac for Radiotherapy: 2019 Update
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Coordination Chemistry of +3 Actinium
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Anders Josefsson
- Author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
- Co-author in Application of a trabecular and cellular model of bone marrow dosimetry for targeted 223Ra therapy
- Co-author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
Haijo Jung
- Co-author in Development of actinium-225 production method using liquid target
Ki-Hye Jung
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
Joseph Jurcic
- Author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
- Author in Alpha-Particle Therapy for Acute Myeloid Leukemia
Kazuya Kabayama
- Author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
Yuta KAIZUKA
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Jan Kalinovsky
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Akimitsu Kanda
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Kazuko Kaneda
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
Choong Mo Kang
- Author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Joo Hyun Kang
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Bergmark Karin
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Sharayu Karkare
- Author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
Jenny Karlsson
- Author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Mattias Karlsson Dinnetz
- Author in Precision Medicine and Innovation Law – Some Considerations
Jay Kehn
- Co-author in Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory
Yona Keisari
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Vanessa Kelly
- Co-author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Itzhak Kelson
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Dimitri Kereselidze
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
BEHLOL KHAN
- Author in Biparatopic targeting of epidermal growth factor receptor positive breast cancer cells using domain I/II and domain III specific antibody conjugates
Sharif Khan
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Dohyun Kim
- Author in FLUKA simulation of Ac-225 production with a medical cyclotron
Wook Kim
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
Hyun-Ah Kim
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Jung Young Kim
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
Kwang Il Kim
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Byung Il Kim
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Annemarie Kip
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
James C Knight
- Co-author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Otto Knoesen
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Karina Knorr
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Konstantin Kokov
- Author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Nobuaki KONO
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
Aruna Korde
- Co-author in The role of IAEA in the development of radiopharmaceutical sciences with focus on alpha emitters
Ján Kozempel
- Author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
- Co-author in PRELIMINARY IN-VITRO STUDY OF 223Ra IMPACT ON SELECTED TISSUE AND TUMOR CELL LINES
Henryk Koziara
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Stosh Kozimor
- Author in Coordination Chemistry of +3 Actinium
Alexandr Kristian
- Co-author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
Leszek Krolicki
- Author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
- Co-author in Improved tumor control and absence of late neurotoxicity using alpha (213Bi) as compared to beta (90Y) labelled-DOTA-Substance P for the treatment of low grade gliomas
Bartosz Królicki
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Hitoshi Kubo
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Ekaterina Kukleva
- Co-author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
Senthil Kumar
- Co-author in Nanoparticles for the treatment of metastatic non small cell lung cancer with 225Ac
Jolanta Kunikowska1
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Alexander Kupriyanov
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
- Co-author in Capabilities of JSC “SSC RIAR” in Producing 227ThCl4
Alexander Kupriyanov
- Co-author in Production and Quality Control of 223RaCl2 and 224RaCl2
Alexey Kupriyanov
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
Donna Kusewitt
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Rostislav Kuznetsov
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
- Co-author in Capabilities of JSC “SSC RIAR” in Producing 227ThCl4
Tony Lahoutte
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
Tony Lahoutte
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Andrew Lakes
- Co-author in Actinium Biokinetics and Dosimetry: What is the Impact of Ac-227 in Accelerator-Produced Ac-225?
Elena Lapshina
- Author in Production of 230Pa from proton-irradiated thorium and developing 230Pa/230U/226Th tandem generator
- Co-author in Various chromatographic schemes for separation of 213Bi from 225Ac
Aasmund Larsen
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Ismaheel Lawal
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Luke Lawrence
- Co-author in Automated Production of Alpha-Emitting Therapeutic Radionuclides
Thuc Le
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Inki Lee
- Author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Chul-Hee Lee
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Kyo Chul Lee
- Co-author in Development of actinium-225 production method using liquid target
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Yong Jin Lee
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Hwunjae Lee
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
Hwan Lee
- Author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Thabo Lengana
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Stéphanie Lerondel
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Eugene Leung
- Co-author in Safe use of Ra-223 radium dichloride (223Ra) across a wide-range of clinical scenarios: A 10-year single-institution radiation safety experience.
Moshe Yair Levy
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Jason S Lewis
- Co-author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Gang Li
- Co-author in Implementation of Single Alpha-Particle Traversal Microdosimetric Model
- Co-author in Microdosimetric and Biokinetic Modelling of Alpha-Immuno-Conjugate Transport in Endothelial Cells
Yawen Li
- Author in Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
LILY LI
- Author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Huizi Keiko Li
- Co-author in Alpha-radioimmunotherapy against liver metastasis of HER2-positive gastric cancer in a mouse model
Francisco Liberal
- Author in In vitro radiobiological effects of Radium-223
- Co-author in Mechanistic modelling of Radium-223 treatment of bone metastases
Laura Lilley
- Co-author in Coordination Chemistry of +3 Actinium
Ilhan Lim
- Co-author in Development of actinium-225 production method using liquid target
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Sang Moo Lim
- Co-author in Development of actinium-225 production method using liquid target
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
- Co-author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Sture Lindegren
- Author in Astatine-211: The Chemistry Infrastructure
- Co-author in A Novel Reaction for “Click”-based 211At-Astatination
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
- Co-author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
Lars Linden
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
Tong Liu
- Author in Implementation of Single Alpha-Particle Traversal Microdosimetric Model
- Co-author in Microdosimetric and Biokinetic Modelling of Alpha-Immuno-Conjugate Transport in Endothelial Cells
Yu Liu
- Author in Novel Neuromorphic Computing based Monte Carlo Simulation of Alpha Particles Penetration into Tumor Cells in Targeted Alpha Therapy
- Co-author in Microdosimetric and Biokinetic Modelling of Alpha-Immuno-Conjugate Transport in Endothelial Cells
Chenchen Liu
- Co-author in Novel Neuromorphic Computing based Monte Carlo Simulation of Alpha Particles Penetration into Tumor Cells in Targeted Alpha Therapy
Yuwei Liu
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
Andrew Lobbezoo
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
Christopher Logothetis
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
John Logue
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Dale Ludwig
- Author in Radiolabeling of DOTA-conjugated Lintuzumab with 225Ac: Comparison of Th-229-produced and High-Energy Proton Accelerator-produced 225Ac
- Co-author in Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225
- Co-author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
- Co-author in Impact of Target Cell Number on Target cell and Tissue Dose for Antibody-Mediated delivery of Alpha-Emitters
Alexey Lyundup
- Co-author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Astri MAALAND
- Co-author in 212Pb-NNV003 as a novel targeted alpha therapy for CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
Robert H. Mach
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Dominic Maertens
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Dominic Maertens
- Author in Ra-226/Ac-225 chemical separation R&D at SCK•CEN
- Co-author in The strategic plans of SCK•CEN towards a routine production of 225Ac from 226Ra
Charles Maitz
- Author in Nanoparticles for the treatment of metastatic non small cell lung cancer with 225Ac
Mehran Makvandi
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Mackenzie Malo
- Author in Assessing Melanin Capabilities in Radiation Shielding and Radioadaptation
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
- Co-author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
- Co-author in Targeted therapy of osteosarcoma with radio-labelled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)
- Co-author in The Use of Radioimmunotherapy for the Treatment of Metastatic Melanoma
Constantin Mamat
- Co-author in Calixarene based ligands for Radium and Barium
- Co-author in Synthesis and Functionalization of Radium-doped Barium Sulfate Nanoparticles
Yoshiyuki Manabe
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
Komal Mandleywala
- Co-author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Adam Mansfield
- Author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Chris Marcus
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
John M. Maris
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Daniel Martinez
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Chris Martinez
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Christopher Massey
- Co-author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
Tara Mastren
- Co-author in A dual generator concept to yield 226Th: an isotope of interest for targeted alpha therapy
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Mikio Matsumoto
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Leonard Mausner
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Raya Mawad
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Daniel McAlister
- Author in Selective Separation of Radium and Actinium from Bulk Thorium Target Material
Stephen McMahon
- Co-author in In vitro radiobiological effects of Radium-223
- Co-author in Mechanistic modelling of Radium-223 treatment of bone metastases
Dmitri Medvedev
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Dmitri Medvedev
- Author in Evaluation of inorganic ion exchange materials for purification of 225Ac from thorium and radium radioisotopes
Jana Merhautová
- Co-author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
Robin Merkx
- Author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
Adrian Merlo
- Author in Improved tumor control and absence of late neurotoxicity using alpha (213Bi) as compared to beta (90Y) labelled-DOTA-Substance P for the treatment of low grade gliomas
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Jasper Mermans
- Co-author in Ra-226/Ac-225 chemical separation R&D at SCK•CEN
Jasper Mermans
- Co-author in The strategic plans of SCK•CEN towards a routine production of 225Ac from 226Ra
Catherine Meyer
- Author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Johansson Mia
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Brian Miller
- Author in Radiation imagers for quantitative, single-particle digital autoradiography of alpha-and beta-particle emitters for targeted radionuclide therapy
Kurt Miller
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Kienna Mills
- Co-author in Glycoprotein 41 targeted radioimmunotherapy as a novel treatment for neuroHIV/AIDS
Katsuyuki Minegishi
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Saed Mirzadeh
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in LANTHANIDE-BASED NANOPARTICLES FOR MULTIMODAL MOLECULAR IMAGING AND TARGETED ALPHA THERAPY
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
- Co-author in Separation of Actinium-225 from Lanthanides Using High Pressure Ion Chromatography
Aviram Mizrachi
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Veronika Mocko
- Co-author in Coordination Chemistry of +3 Actinium
Azim MOHAMMAD ANWAR-UL
- Co-author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
Kgomotso Mokoala
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Janneke Molkenboer-Kuenen
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
Jacques Monteil
- Co-author in Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma
Matthew Moran
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Alfred Morgenstern
- Author in 225Ac-PSMA617 for therapy of prostate cancer – where do we stand?
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
- Co-author in Alpha-particle nanotherapeutics against recurrent, chemoresistant Triple Negative Breast Cancer
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
- Co-author in Improved tumor control and absence of late neurotoxicity using alpha (213Bi) as compared to beta (90Y) labelled-DOTA-Substance P for the treatment of low grade gliomas
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
Amanda Morgenstern
- Co-author in Coordination Chemistry of +3 Actinium
Hugo Moriera
- Co-author in In vitro radiobiological effects of Radium-223
- Co-author in Mechanistic modelling of Radium-223 treatment of bone metastases
Louis Moskven
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
Pinku Mukherjee
- Co-author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Peter Mulders
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
Gabriele Multhoff
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
Dominik Mumberg
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Karen Murphy
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
Brahim Mustapha
- Co-author in Development of 211At production via continuous extraction of 211Rn
Ali Muzammil
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Jenasee Mynerich
- Author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
Kojiro Nagata
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Kotaro Nagatsu
- Author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Laurent NAVARRO
- Co-author in Advances in the radiolabeling of antibodies with astatine-211: toward simplified procedures and improved radiochemical yields
Jessie Nedrow
- Author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
Sten Nilsson
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Ken-ichi Nishijima
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Ichiro Nishinaka
- Author in Astatine and iodine chemical species in solutions prepared by dry distillation
- Co-author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
Woo Chul Noh
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
Jerry Nolen
- Author in Development of 211At production via continuous extraction of 211Rn
Jeffrey Norenberg
- Author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Meiring Nortier Nortier
- Author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Monique Nysus
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Edouard nzambimana
- Author in Theoretical study of the Thorium structural in solution by EXAFS techniques
Ellen O'Brien
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Se Young Oh
- Author in Development of actinium-225 production method using liquid target
Yasuhiro Ohshima
- Author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
- Co-author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
Eric Olivas
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Lukas Ondrák
- Author in PRELIMINARY IN-VITRO STUDY OF 223Ra IMPACT ON SELECTED TISSUE AND TUMOR CELL LINES
Kazuhiro Ooe
- Author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Maarten Ooms
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Egbert Oosterwijk
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
Kelly Orcutt
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
Noboru Oriuchi
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Johnnie Orozco
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Chris Orvig
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Joao Alberto Osso Jr.
- Co-author in The role of IAEA in the development of radiopharmaceutical sciences with focus on alpha emitters
Valentina Ostapenko
- Co-author in Production of 230Pa from proton-irradiated thorium and developing 230Pa/230U/226Th tandem generator
Joe M. O'Sullivan
- Author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
- Co-author in In vitro radiobiological effects of Radium-223
- Co-author in Mechanistic modelling of Radium-223 treatment of bone metastases
Stig Palm
- Author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
- Co-author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
Hyeon Park
- Co-author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
Jae Park
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Ji-Ae Park
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Gannon Parker
- Author in Separation of Ac-225 from lanthanide fission products using a reverse phase chromatographic process incorporating a solvent impregnated resin
Vimal Patel
- Co-author in Radiolabeling of DOTA-conjugated Lintuzumab with 225Ac: Comparison of Th-229-produced and High-Energy Proton Accelerator-produced 225Ac
Bruce R. Pawel
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Dariusz Pawlak
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Allison Peacock
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Maria Guadalupe Jaraquemada Pelaez
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Alexander Perl
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Yury Perminov
- Co-author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Dahm-Kähler Pernilla
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Randy Perron
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
Randy Perron
- Co-author in Selective Separation of Radium and Actinium from Bulk Thorium Target Material
William Peters
- Co-author in High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac
Turner Philip
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
Kayla Phillips
- Co-author in Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory
Anja Pickhard
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
Hans-Jürgen Pietzsch
- Co-author in Calixarene based ligands for Radium and Barium
- Co-author in Synthesis and Functionalization of Radium-doped Barium Sulfate Nanoparticles
Guido Piontek
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
Donika Plyku
- Co-author in Small Scale Modeling and Dosimetry for the Salivary Gland: Application to 177Lu- and 225Ac-PSMA Therapy
Martin G. Pomper
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
Aron Popovtzer
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Sophie Poty
- Author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Aprameya Prasad
- Co-author in Alpha-particle nanotherapeutics against recurrent, chemoresistant Triple Negative Breast Cancer
Oliver W. Press
- Co-author in Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
Kevin Prise
- Author in Mechanistic modelling of Radium-223 treatment of bone metastases
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
- Co-author in In vitro radiobiological effects of Radium-223
Mikhail Proshin
- Co-author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Marek Pruszynski
- Author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
Daniel A. Pryma
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Isabelle Quelven
- Co-author in Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma
Rene Raavé
- Co-author in Therapeutic efficacy of 225Ac-containing polymersomes
Valery Radchenko
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
- Co-author in This is a placeholder abstract
Caius Radu
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Hultborn Ragnar
- Co-author in Estimation of long-term risks for cancer induction following adjuvant targeted alpha therapy with curative intent.
- Co-author in Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations
Puri Rahul
- Co-author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Pichai Raman
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Caterina Ramogida
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
Akhila Rao
- Co-author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
Komal S. Rathi
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Stephanie Rathmann
- Author in A Versatile Immune-Stimulatory Actinium-225 Complex for Combination Radiotherapy and Antibody Recruiting Therapy
Sudhir Rawal
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Sangeeta Ray
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
Nitya Ray
- Co-author in Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225
- Co-author in Radiolabeling of DOTA-conjugated Lintuzumab with 225Ac: Comparison of Th-229-produced and High-Energy Proton Accelerator-produced 225Ac
Kelly Redmond
- Co-author in In vitro radiobiological effects of Radium-223
Julian Rees
- Author in Bioconjugation of actinides using a peptoid scaffold
- Co-author in Actinium Biokinetics and Dosimetry: What is the Impact of Ac-227 in Accelerator-Produced Ac-225?
Sean W. Reilly
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Thomas Reiner
- Co-author in PET imaging of DNA damage response following 225Ac-radioimmunotherapy in a pancreatic ductal adenocarcinoma mouse model.
Falco Reissig
- Author in Synthesis and Functionalization of Radium-doped Barium Sulfate Nanoparticles
- Co-author in Calixarene based ligands for Radium and Barium
Igor Reshetov
- Author in 212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors
Margitta Retz
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Florette Reyneke
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Timothy Richardson
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
David Rickles
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
Mark Rijpkema
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
Olivier Rixe
- Co-author in Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and Histopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors
David Rizzieri
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Andrew Robertson
- Author in Ac-225 production using TRIUMF's 500 MeV cyclotron
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
J. David Robertson
- Co-author in Nanoparticles for the treatment of metastatic non small cell lung cancer with 225Ac
Gail Roboz
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Magdalena Rodak
- Co-author in The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
Jessika V. Rojas
- Co-author in LANTHANIDE-BASED NANOPARTICLES FOR MULTIMODAL MOLECULAR IMAGING AND TARGETED ALPHA THERAPY
Rafał Rola
- Co-author in Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
Evgeny Romanov
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
Eli Rosenfeld
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
David Rotsch
- Co-author in Development of 211At production via continuous extraction of 211Rn
Julie Rousseau
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Thomas Ruth
- Author in Has the dream come true? A retrospective look at the development of alpha therapy and its promise for the future.
Olav B Ryan
- Author in In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate
- Co-author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Fred Saad
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Juan P. Sade
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Meelad Saekheie
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
Amal Saidi
- Author in 212Pb-NNV003 as a novel targeted alpha therapy for CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
- Co-author in Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Catherine Sai-Maurel
- Co-author in Optimization of dosimetry in alphatherapy: microlocalisation of 223Ra in mouse models of metastasis from prostate cancer and renal cell carcinoma.
Tetsuya SAKASHITA
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
Minu Samanta
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Uma Sampathkumaran
- Co-author in Development of 211At production via continuous extraction of 211Rn
Biggart Sandra
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
Nicole Sarden
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Oliver Sartor
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Ichiro SASAKI
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
- Co-author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
Mike Sathekge
- Author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Yui SATO
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Paul Schaffer
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
- Co-author in Evaluation of specific activity and stable impurities in 225Ac derived from ISAC and 229Th decay.
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Christoph Schatz
- Co-author in Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
Michael Schmidt
- Co-author in Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy
Martin Schostak
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Christof Seidl
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
Min-Ki Seong
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
George Sgouros
- Author in Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225
- Author in Impact of Target Cell Number on Target cell and Tissue Dose for Antibody-Mediated delivery of Alpha-Emitters
- Co-author in Application of a trabecular and cellular model of bone marrow dosimetry for targeted 223Ra therapy
- Co-author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
- Co-author in Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
- Co-author in Small Scale Modeling and Dosimetry for the Salivary Gland: Application to 177Lu- and 225Ac-PSMA Therapy
George Sgouros
- Co-author in Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Farah Shanoon
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Eku Shimosegawa
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
Saki Shimoyama
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Atsushi Shimoyama
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
Atsushi Shinohara
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Yoshifumi Shirakami
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Abigail Shtekler
- Co-author in Evaluation of 225Ac-anti-VLA-4 for targeted α-therapy for treatment of metastatic melanoma
Michael Siegl
- Author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
Ryan Simms
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Amitabh Singh
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Roger Slavik
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
K Smart
- Co-author in Evaluation of novel antibodies to Centrin-1 for radioimmunotherapy of pancreatic cancer
Stavroula Sofou
- Author in Alpha-particle nanotherapeutics against recurrent, chemoresistant Triple Negative Breast Cancer
Jeongseog Song
- Co-author in Development of 211At production via continuous extraction of 211Rn
Tania Stallons
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Benjamin Stein
- Co-author in Coordination Chemistry of +3 Actinium
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Jörg Steinbach
- Co-author in Calixarene based ligands for Radium and Barium
- Co-author in Synthesis and Functionalization of Radium-doped Barium Sulfate Nanoparticles
Cora N. Sternberg
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Palm Stig
- Co-author in Astatine-211: The Chemistry Infrastructure
Thierry Stora
- Co-author in ISOL technique for the production of 225Ac at CERN-MEDICIS
Yaryna Storozhuk
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Daniel Stracener
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
- Co-author in Separation of Actinium-225 from Lanthanides Using High Pressure Ion Chromatography
Daniel Stracner
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Andreea STUPARU
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Petra Suchánková
- Co-author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
Jain Suneil
- Co-author in Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Metastatic Prostate Cancer in a novel clinical trial with Radium-223 and External Beam Radiotherapy
Hiroyuki Suzuki
- Author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
- Co-author in Astatine and iodine chemical species in solutions prepared by dry distillation
Hisashi Suzuki
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Kazuhiro Takahashi
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Vineet Talwar
- Co-author in Safety profile and therapeutic efficacy of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients with low performance status
Chengbo Tan
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Hiroshi TANAKA
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Valery Tarasov
- Co-author in Alternative Options to Produce 225Ac for Nuclear Medicine
Maho TATSUTA
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Robert Tauber
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Keisha Thomas
- Co-author in Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
Jana Thomson
- Author in This is a placeholder abstract
Daniel Thorek
- Co-author in Application of a trabecular and cellular model of bone marrow dosimetry for targeted 223Ra therapy
- Co-author in Automated Production of Alpha-Emitting Therapeutic Radionuclides
Bertrand Tombal
- Co-author in Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
Julien Torgue
- Co-author in 212Pb-NNV003 as a novel targeted alpha therapy for CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
- Co-author in Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma
- Co-author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
Miguel Toro-Gonzalez
- Author in LANTHANIDE-BASED NANOPARTICLES FOR MULTIMODAL MOLECULAR IMAGING AND TARGETED ALPHA THERAPY
Atsushi Toyoshima
- Author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
William Tse
- Co-author in A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Atsushi Tsuji
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Izabela Tworowska
- Author in Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
- Co-author in Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212
Tomoya UEHARA
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Naoyuki Ukon
- Author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Jana Vachelova
- Co-author in PRELIMINARY IN-VITRO STUDY OF 223Ra IMPACT ON SELECTED TISSUE AND TUMOR CELL LINES
Starovoitova Valeriia
- Co-author in The role of IAEA in the development of radiopharmaceutical sciences with focus on alpha emitters
John Valliant
- Co-author in A Versatile Immune-Stimulatory Actinium-225 Complex for Combination Radiotherapy and Antibody Recruiting Therapy
John Valliant
- Co-author in IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA double-stranded breaks and induces regression in preclinical models of human cancer
Shelley Van Cleve
- Author in Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory
Aleksandr Vasiliev
- Author in Various chromatographic schemes for separation of 213Bi from 225Ac
- Co-author in Production of 230Pa from proton-irradiated thorium and developing 230Pa/230U/226Th tandem generator
James Verdone
- Co-author in PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity
Marjolein Verhoeven
- Co-author in Quantified cell binding of astatinated immunoconjugates on ovarian cancer cell spheroids by alpha camera imaging
Christiaan Vermeulen
- Co-author in Proton Beam Production of Curie Scale Ac-225 at 100 MeV and Below
Gottumukkala Vijay
- Co-author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Raja Solomon Viswas
- Author in Targeted alpha particle therapy of EGFR-positive breast cancer using site-specifically labeled 225Ac–dN-SpyCatcher-SpyTag-nimotuzumab
Martin Vlk
- Co-author in PRELIMINARY IN-VITRO STUDY OF 223Ra IMPACT ON SELECTED TISSUE AND TUMOR CELL LINES
- Co-author in Tuning of the Radium biodistribution by dietary supplements in a CD1 mice model.
Oliver von Ahsen
- Co-author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Mariza Vorster
- Co-author in 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Nana WASHIYA
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Kohshin Washiyama
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
- Co-author in Development of 211At production via continuous extraction of 211Rn
Tadashi Watabe
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Increased uptake of At-211 in thyroid gland by the preparation with ascorbic acid for targeted alpha therapy of thyroid cancer
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
Shigeki Watanabe
- Author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
- Co-author in Radiohalogenated neopentyl derivatives: A novel scaffold for radioiodinated and astatinated compounds of high stability to in vivo dehalogenation
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
Wolfgang Weber
- Co-author in Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
- Co-author in The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
Liu Wei
- Co-author in Therapeutic efficacy and dosimetry of targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer
Jamey Weichert
- Co-author in 225Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer.
Michael Wheatcroft
- Co-author in 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
Katrine Wickstroem
- Author in Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
D. Scott Wilbur
- Co-author in Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
- Co-author in New Bifunctional Chelators for 225Ac and 227Th Radioimmunotherapy
Martin Wilkovitsch
- Co-author in A Novel Reaction for “Click”-based 211At-Astatination
Raymond Winter
- Co-author in Development of 211At production via continuous extraction of 211Rn
Manfred Wirth
- Co-author in Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sang-Keun Woo
- Author in Estimation of internal dosimetry of 64Cu and 225Ac labeled PSMA-617
- Author in Image-based approach for absorbed dose estimation of 64Cu/225Ac-DOTA-trastuzumab using Monte Carlo simulation
- Co-author in Dosimetry Prediction of 225Ac-NOTA-Trastuzumab Based on 64Cu-NOTA-Trastuzumab in Breast Cancer: Preliminary Microdose Clinical Trial
- Co-author in Synthesis and evaluation of 64Cu (225Ac)-labeled rituximab for CD20 expression
Pamela Woodard
- Co-author in Automated Production of Alpha-Emitting Therapeutic Radionuclides
Joseph Wright
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
- Co-author in Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes
Shu-ta Wu
- Co-author in Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer
Lance Wyant
- Co-author in Chemical Purification of Actinium-225 from Proton-Irradiated Thorium Targets
Catarina Xavier
- Co-author in Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
Tong Xu
- Author in Microdosimetric and Biokinetic Modelling of Alpha-Immuno-Conjugate Transport in Endothelial Cells
- Co-author in Implementation of Single Alpha-Particle Traversal Microdosimetric Model
Kuiying Xu
- Co-author in Sensitivity to a poly(ADP-ribose) polymerase 1 (PARP-1) targeting alpha particle therapeutic in neuroblastoma is characterized by increased relative biological effectiveness (RBE) compared to gamma irradiation
Keiichi YAMADA
- Co-author in Synthesis of 4-[$^{211}$At]astato-L-phenylalanine via electrophilic demetallation from a silylprecursor
Hua Yang
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
Tsuneo Yano
- Author in Consideration toward Safety Guidance for Targeted Alpha Therapy in Japan
Yuichiro YOKOTA
- Co-author in RNA-seq reveals tumor radiation response and novel molecular targets on α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma
Takashi Yoshimura
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Ali Younes
- Author in Evaluation of inorganic ion exchange materials for purification of 225Ac from thorium and radium radioisotopes
Mike Zamiara
- Co-author in High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac
Stefan Zeisler
- Co-author in Ac-225 production using TRIUMF's 500 MeV cyclotron
Patrick Zerkel
- Co-author in Automated Production of Alpha-Emitting Therapeutic Radionuclides
Zijian Zhang
- Co-author in Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University
- Co-author in Isolation of At-211 by dry-distillation under oxidative conditions for targeted alpha therapy in Osaka University
Ming-Rong Zhang
- Co-author in A production challenge of Ac-225 from RaCO3 target activated by vertical beam
Shongji Zhao
- Co-author in Biodistribution and dosimetry of free 211At and meta-[211At]astatobenzylguanidine (MABG) in normal mice
Shaofei Zhu
- Co-author in Development of 211At production via continuous extraction of 211Rn
Boris Zhuikov
- Co-author in Production of 230Pa from proton-irradiated thorium and developing 230Pa/230U/226Th tandem generator
- Co-author in Various chromatographic schemes for separation of 213Bi from 225Ac
Sabine Zitzmann-Kolbe
- Author in Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
Lionel zuckier
- Co-author in Safe use of Ra-223 radium dichloride (223Ra) across a wide-range of clinical scenarios: A 10-year single-institution radiation safety experience.

Choose timezone

Targeted Alpha Therapy Symposium